Esobose Capsule SR contains a combination of Domperidone 30mg and Esomeprazole 40mg, formulated to manage gastrointestinal disorders associated with acid reflux and delayed gastric emptying. Esomeprazole, a proton pump inhibitor, effectively suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, thereby promoting ulcer healing and symptom relief in conditions such as gastroesophageal reflux disease (GERD), erosive esophagitis, and Zollinger-Ellison syndrome. Domperidone, a peripheral dopamine D2 receptor antagonist, enhances gastrointestinal motility and accelerates gastric emptying without affecting gastric acid secretion, providing symptomatic relief from nausea, vomiting, bloating, and discomfort related to delayed gastric emptying or gastroparesis. The sustained-release formulation ensures prolonged therapeutic plasma concentrations, improving patient compliance and efficacy. Esobose Capsule SR is indicated for patients requiring both acid suppression and prokinetic therapy, particularly in cases where monotherapy is insufficient. It should be used under medical supervision, considering contraindications such as hypersensitivity to components, prolactinoma, or cardiac arrhythmias. Caution is advised in patients with hepatic or renal impairment. Common adverse effects may include headache, dry mouth, or gastrointestinal disturbances. Regular monitoring and adherence to prescribed dosage are essential for optimal outcomes.